Clinical Trial Update: Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a hypomethylating agent in combination with venetoclax after allogeneic stem cell transplantation in high-risk myeloid maligna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Malignancies

Drugs mentioned

• Hypomethylating agent
• Venetoclax (venetoclax)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Hypomethylating Agent, Venetoclax | Phase 2 | Status: RECRUITING